- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | ROUNDUP: Orion Q2 Profit Rises; Revises Outlook | 381 | AFX News | HELSINKI (dpa-AFX) - (Adds Outlook)For the full year, Orion Oyj (0M2N.L) now expects operating profit of EUR 650 million to EUR 750 million, compared with the previous expectation of EUR 600... ► Artikel lesen | |
| Fr | Orion-Aktie hebt ab: Bayer-Partner mit Top-Zahlen | 934 | Der Aktionär | Der finnische Pharma-Konzern Orion bleibt auf einem dynamischen Wachstumskurs. Sowohl Umsatz als auch Ergebnis haben die Nordeuropäer im zweiten Quartal kräftig steigern können. Als Wachstumstreiber... ► Artikel lesen | |
| Fr | Orion Oyj Reveals Advance In Q2 Income | 348 | AFX News | HELSINKI (dpa-AFX) - Orion Oyj (0M2N.L) reported earnings for its second quarter that Increased, from last yearThe company's bottom line came in at EUR140.2 million, or EUR1 per share. This... ► Artikel lesen | |
| Fr | Orion Oyj: Orion Group Half-Year Financial Report January-June 2026 | 429 | GlobeNewswire (Europe) | ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1-6/2026 17 JULY 2026 at 12:00 EEST Orion Group Half-Year Financial Report January-June 2026 April-June 2026 Highlights Net sales totalled EUR 521.6... ► Artikel lesen | |
| Fr | Orion Oyj: Orion Corporation's financial reporting and Annual General Meeting in 2027 | 4 | GlobeNewswire (USA) | ||
| 15.07. | Orion Oyj: 45,611 Orion Corporation A shares converted into B shares | 4 | GlobeNewswire (USA) | ||
| 06.07. | Shilpa Medicare Limited: Orion und Shilpa Medicare bauen Partnerschaft aus, um Nivolumab Biosimilar für Europa zu entwickeln und zu liefern | 505 | Business Wire | Shilpa Medicare Limited gab bekannt, dass seine hundertprozentige Tochtergesellschaft, Shilpa Biologicals Private Limited, mit der Orion Corporation eine Vereinbarung über die gemeinsame Entwicklung... ► Artikel lesen | |
| ORION OYJ ADR Aktie jetzt für 0€ handeln | |||||
| 06.07. | Shilpa Medicare Limited: Orion Corporation and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe | 481 | Business Wire | Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous... ► Artikel lesen | |
| 03.07. | Orion Oyj: Orion publishes Half-Year Report for January-June 2026 and holds a webcast on 17 July 2026 | 4 | GlobeNewswire (USA) | ||
| 30.06. | Shilpa Medicare jumps as subsidiary signs biosimilar pact with Finland's Orion | 3 | capitalmarket.com | ||
| 30.06. | Orion Oyj: Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market | 555 | GlobeNewswire (Europe) | ORION CORPORATION PRESS RELEASE 30 JUNE 2026 at 8.00 EEST Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market Orion Pharma ("Orion") and Shilpa... ► Artikel lesen | |
| 23.06. | Orion Oyj: Orion Pharma's ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission | 523 | GlobeNewswire (Europe) | ORION CORPORATION PRESS RELEASE 23 JUNE 2026 at 9:30 EEST Orion Pharma's ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission Orion Corporation... ► Artikel lesen | |
| 15.06. | Orion Oyj: Disclosure Under Chapter 9 Section 10 of the Securities Market Act | 5 | GlobeNewswire (USA) | ||
| 10.06. | Orion Oyj: Disclosure Under Chapter 9 Section 10 of the Securities Market Act | 3 | GlobeNewswire (USA) | ||
| 05.06. | Orion Oyj: Disclosure Under Chapter 9 Section 10 of the Securities Market Act | 2 | GlobeNewswire (USA) | ||
| 30.05. | Orion Oyj: Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours | 269 | GlobeNewswire (Europe) | ORION CORPORATION PRESS RELEASE 30 MAY 2026 at 21:30 EEST Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours... ► Artikel lesen | |
| 21.05. | Orion Oyj: Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO Annual Meeting | 3 | GlobeNewswire (USA) | ||
| 15.05. | Orion Oyj: 105,950 Orion Corporation A shares converted into B shares | 2 | GlobeNewswire (USA) | ||
| 12.05. | Orion Oyj: Orion Animal Health receives US FDA approval for Tessie (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs | 737 | GlobeNewswire (Europe) | ORION CORPORATION PRESS RELEASE12 MAY 2026 at 10:30 EEST Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation... ► Artikel lesen | |
| 04.05. | Orion Oyj: Managers' transactions - Veli-Matti Mattila | 4 | GlobeNewswire (USA) |
1 2 3 4 Weiter >>
67 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CHINA PHARMA HOLDINGS | 8,640 | +0,23 % | China Pharma: Keine Erklärung für ungewöhnliche Handelsaktivitäten | ||
| ZHENGYE BIOTECHNOLOGY | 2,840 | -0,35 % | Morning Market Movers: Zhengye Biotechnology, Lisata Therapeutics, Meiwu Technology, Danaher Corporation See Big Swings | WASHINGTON (dpa-AFX) - At 9:00 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 43,190 | -0,02 % | Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last? | ||
| AQUESTIVE THERAPEUTICS | 4,040 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Reaffirms guidance to resubmit Anaphylm (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 77,68 | +0,50 % | Motorola Solutions Foundation and Calculated Genius Honor Chicagoland Future Engineers With 2026 Bright Minds, Bold Futures Scholarship | NORTHAMPTON, MA / ACCESS Newswire / June 30, 2026 / Ten extraordinary Chicagoland high school seniors recently gathered at Motorola Solutions' global headquarters in Chicago, joined by family members... ► Artikel lesen | |
| LB PHARMACEUTICALS | 32,280 | -0,09 % | BMO initiates LB Pharmaceuticals stock at Outperform on drug data | ||
| JUPITER NEUROSCIENCES | 0,166 | -2,30 % | PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002 | TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| TURN THERAPEUTICS | 10,180 | 0,00 % | Turn Therapeutics Inc. - 8-K, Current Report | ||
| NOVO NORDISK | 42,790 | -1,45 % | Johnson & Johnson, GSK und Co.: Warum der Wettlauf um Zelltherapie-Plattformen gerade erst beginnt | ||
| VYNE THERAPEUTICS | 0,888 | -0,52 % | VYNE Therapeutics Inc.: VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience | NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced that its Board of Directors has approved a reverse stock split of VYNE's... ► Artikel lesen | |
| TRISALUS LIFE SCIENCES | 4,340 | 0,00 % | Canaccord reiterates TriSalus stock Buy rating after KOL event | ||
| GILEAD SCIENCES | 113,86 | -0,33 % | Big Pharma sucht den nächsten Blockbuster - weshalb Zelltherapien wieder stärker in den Fokus rücken | ||
| WELLGISTICS HEALTH | 3,510 | -0,28 % | Wellgistics Health, Inc. Officially Changes Corporate Name To DataMEDS AI, Inc. | Leading Health IT Company's Rebranding Reflects Updated Healthcare Ecosystem Aligned with AI Integration to Optimize Patient Control of Healthcare Data
TAMPA, Fla.... ► Artikel lesen | |
| CUMBERLAND PHARMACEUTICALS | 7,870 | +0,25 % | Apotex Inc.: Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals | TORONTO, July 1, 2026 /PRNewswire/ - Apotex Health Corp. ("Apotex") (TSX: APTX), the largest Canadian-based pharmaceutical company, today announced the closing... ► Artikel lesen | |
| NOVARTIS | 133,92 | -0,74 % | Neuer Meilenstein: FDA-Entscheidung sorgt für Hoffnung: Novartis gelingt Durchbruch | © Foto: Spencer Jones - picture alliance / Glasshouse ImagesDie FDA hat Fabhalta von Novartis vollständig zugelassen. Das Medikament verlangsamt den Verlust der Nierenfunktion bei einer schweren Autoimmunerkrankung.Novartis... ► Artikel lesen |
Das Unternehmen ORION OYJ ADR kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,69 % bei einem Aktienkurs von 38,200 Euro. Aus der Ausschüttung der letzten 12 Monate von insgesamt 0,00 Euro errechnet sich eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ORION OYJ ADR finden Sie auf Wallstreet Online.